Drugs / REGE pro
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03942250 | Jan → Dec 2017 | chronic ulcer of skin, epidermolysis bullosa dystrophica | Egyptian Atomic Energy Authority | Completed | No outcome recorded |
| — | NCT03440541 | Aug 2015 → Feb 2016 | psoriasis | Egyptian Atomic Energy Authority | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGE pro | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03440541 ↗ |
| Known as | REGE pro gel | “Human amniotic membrane extra-cellular matrix was purchased from National center for radiation research and technology, Egypt, under commercial name REGE pro gel.” NCT03440541 ↗ |
| Modality | Other / unclassified | “REGE pro is a patch of human amniotic membrane sterilized by gamma radiation” NCT03440541 ↗ |
| Route | Topical | “as a topical treatment” NCT03440541 ↗ |